Skip to main content
. Author manuscript; available in PMC: 2019 Mar 22.
Published in final edited form as: Bioconjug Chem. 2018 Sep 24;29(10):3476–3482. doi: 10.1021/acs.bioconjchem.8b00632

Figure 1. A summary of the biodistribution of 89Zr-atezo over time in tumor bearing animals.

Figure 1.

A. ImmunoPET (left) and biodistribution studies (right) from selected tissues shows the accumulation of 89Zr-atezo in intact male C57BL/6J mice with subcutaneous B16F10 tumors. Persistently high uptake of the radiotracer was observed in the tumor, spleen, liver and kidney. The location of the tumor on PET/CT is indicated with a white arrow. 89Zr-atezo was administered at a specific activity of 1.53 μCi/μg. B. ImmunoPET (left) and biodistribution studies (right) from selected tissues shows the accumulation of 89Zr-atezo in intact male nu/nu mice with subcutaneous H1975 tumors. Similar qualitative trends in the biodistribution of normal tissues were observed compared to the data collected from C57BL/6J mice. Tumor uptake in H1975 was lower than that observed in B16F10 tumors, consistent with the relative expression levels of PD-L1. The location of the tumor on PET/CT is indicated with a white arrow. 89Zr-atezo was administered at a specific activity of 2.17 μCi/μg.